Amanote Research
Register
Sign In
Evaluation of an Anti-Her2 Nanobody Labeled With 225Ac for Targeted Particle Therapy of Cancer
doi 10.1021/acs.molpharmaceut.7b00985.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
Targeted Therapy for HER2 Positive Breast Cancer
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
225Ac-Psma-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Targeted Lapatinib Anti-Her2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem
Functionalized NaA Nanozeolites Labeled With 224,225Ra for Targeted Alpha Therapy
Journal of Nanoparticle Research
Materials Science
Nanoscience
Condensed Matter Physics
Molecular Physics,
Simulation
Atomic
Bioengineering
Modeling
Nanotechnology
Chemistry
Optics
Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination With Photochemical Internalization
Molecular Pharmaceutics
Drug Discovery
Molecular Medicine
Pharmaceutical Science
Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Clinical Cancer Research
Cancer Research
Oncology
A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
Cancer Research
Cancer Research
Oncology
Targeted Alpha Therapy With Astatine-211-Labeled Anti-Psca A11 Minibody Shows Antitumor Efficacy in Prostate Cancer Xenografts and Bone Microtumors
EJNMMI Research
Nuclear Medicine
Radiology
Imaging
Efficacy and Safety of HER2-Targeted Agents for Breast Cancer With HER2-Overexpression: A Network Meta-Analysis
PLoS ONE
Multidisciplinary
